Stockpiled Ebola vaccines trigger antibody response against Bundibugyo virus in lab tests

A highly contagious Ebola microorganism species, Bundibugyo microorganism (BDBV), has driven respective outbreaks since 2007, including the ongoing outbreak successful the Democratic Republic of Congo and Uganda successful 2026. Bundibugyo microorganism causes terrible viral hemorrhagic fever that affects aggregate organ systems, damages humor vessels and tin advancement to terrible symptoms, including bleeding and shock. Because determination was nary licensed vaccine designed specifically for the virus, researchers wanted to cognize whether vaccines already utilized for the much communal Zaire ebolavirus could beryllium repurposed to assistance support radical against Bundibugyo virus.